<DOC>
	<DOCNO>NCT01041222</DOCNO>
	<brief_summary>This study test safety , tolerability pharmacokinetics single dos ISIS 333611 administer spinal canal 12 hour infusion .</brief_summary>
	<brief_title>Safety , Tolerability , Activity Study ISIS SOD1Rx Treat Familial Amyotrophic Lateral Sclerosis ( ALS ) Caused SOD1 Gene Mutations</brief_title>
	<detailed_description>This study test safety , tolerability , pharmacokinetics single dos ISIS 333611 administer 12-hour intrathecal infusion . Four dose level ( 0.15 , 0.5 , 1.5 3 mg ) evaluate sequentially . The volume infusion 0.25 mL/12 hour . Each dose level study cohort 8 patient 6 randomize active treatment ISIS 333611 2 randomize placebo .</detailed_description>
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Motor Neuron Disease</mesh_term>
	<mesh_term>Amyotrophic Lateral Sclerosis</mesh_term>
	<mesh_term>Superoxide Dismutase</mesh_term>
	<criteria>Clinical sign weakness attribute ALS . Familial ALS document SOD1 gene mutation . Age 18 year old . Capable provide informed consent willing comply trial procedure time commitment . Vital capacity ( VC ) least 50 % predict value gender , height age screen use invasive respiratory support . If taking riluzole , patient must stable dosage least 30 day prior start study expect remain dosage end study . Medically able undergo temporary insertion intrathecal catheter . Normal test result coagulation parameter . Treatment another investigational drug ALS ( e.g . pyrimethamine , ceftriaxone , lithium , tamoxifen , arimoclomol , high dose creatine , biological agent , device within 1month Screening 5 halflives study agent , whichever longer . No prior treatment siRNA , cell transplant , gene therapy allow . Dosing ISIS 333611CS1 previous dose cohort within 60 day screen . Presence follow clinical condition : 1 . Drug abuse alcoholism within one year Screening visit . 2 . Unstable cardiac , pulmonary , renal , hepatic , endocrine , hematologic function , active infectious disease . 3 . Documented history HIV infection . 4 . Unstable psychiatric illness define psychosis untreated major depression within 90 day Screening Visit . Any condition may impact intrathecal infusion include : 1 . History structural spinal disease include tumor hyperplasia . 2 . Presence implant shunt drainage CSF implant CNS catheter . 3 . Clinically significant abnormality hematology clinical chemistry parameter assess Site Investigator Screening visit . 4 . Ongoing medical condition accord Site Investigator would interfere conduct assessment study . Examples medical disability ( e.g. , severe degenerative arthritis , compromise nutritional state , peripheral neuropathy ) would interfere assessment safety efficacy study material device performance , would compromise ability patient undergo study procedure . 5 . ALT AST &gt; /= 3 x ULN , unless discuss approve Medical Monitor .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2012</verification_date>
	<keyword>Familial ALS</keyword>
	<keyword>ALS</keyword>
	<keyword>SOD1 Protein</keyword>
	<keyword>ISIS 333611</keyword>
	<keyword>SOD1Rx</keyword>
</DOC>